
Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.

Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.

Experts in endocrinology and cardiology review novel agents in the pipeline for the management of hypercholesterolemia and ASCVD.

Erin D. Michos, MD, MHS, leads a discussion on selecting the appropriate patient populations for the use of bempedoic acid when managing atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Christie Ballantyne, MD, leads a discussion on the use of bempedoic acid for the management of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia as seen in the CLEAR studies.

Erin D. Michos, MD, MHS; Christie Ballantyne, MD; Yehuda Handelsman, MD; and Paul S. Jellinger, MD, MACE, address the use of combination therapies and statin intolerance in patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Matthew J. Budoff, MD; Paul S. Jellinger, MD, MACE; Erin D. Michos, MD, MHS; Yehuda Handelsman, MD; and Christie Ballantyne, MD, comment on the use of icosapent ethyl in reducing atherosclerotic cardiovascular disease (ASCVD) events and managing lipid disorders.

Health care experts discuss use of older agents to control atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia in certain patient populations.

Christie Ballantyne, MD, leads a discussion on the efficacy and safety of bempedoic acid for the management of ASCVD and hypercholesterolemia.

Matthew J. Budoff, MD; Erin D. Michos, MD, MHS; and Paul S. Jellinger, MD, MACE, discuss the role of statins, ezetimibe, and PSCK9 inhibitors for patients with ASCVD and hypercholesterolemia.

Christie Ballantyne, MD, and Erin D. Michos, MD, MHS, explore the impact of lifestyle changes on managing ASCVD and hypercholesterolemia.

Expert endocrinologists and cardiologists review the role of DCRM multispecialty practice recommendations and the use of combination therapy for patients with ASCVD and hypercholesterolemia.

Drs Erin D. Michos, Matthew J. Budoff, Paul S. Jellinger, and Yehuda Handelsman, share their approach to incorporating guideline recommendations for the management of patients with ASCVD and hypercholesterolemia in clinical practice.

Dr Christie Ballantyne leads a discussion on how the management of patients with ASCVD and hypercholesterolemia has changed over the years.

Yehuda Handelsman, MD; Christie Ballantyne, MD; Paul S. Jellinger, MD, MACE; and Erin D. Michos, MD, MHS, comment on the impact of diabetes on chronic kidney disease and cardiovascular disease.

Matthew J. Budoff, MD; Christie Ballantyne, MD; and Paul S. Jellinger, MD, MACE, discuss the incidence and prevalence of atherosclerotic cardiovascular diseases (ASCVD) associated with hypercholesterolemia and risk factors for disease.